Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2015.08.182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcatheter edge-to-edge repair for the management of secondary mitral regurgitation - CRT 2025 Beyond the Guidelines.
Cardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFEffects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study.
Diabetes Res Clin Pract
September 2025
Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy; Pollution and Cardiovascular Diseases Research Centre, University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Type-2-diabetes-mellitus (T2DM) impairs outcomes in patients undergoing cardiac-resynchronization-therapy-with-defibrillator (CRTd).While both sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have cardiovascular benefits, their combination impact in CRTd-treated T2DM patients remains unclear.
Methods: In this prospective multicenter observational study, 2,257 T2DM patients treated with CRTd were stratified into three groups: SGLT2i monotherapy (n 874), GLP-1RAs monotherapy (n 808), and combination therapy with GLP-1RAs/SGLT2i (n 575).
Cardiac resynchronization therapy in cancer patients with chemotherapy-induced cardiomyopathy: a mini review.
Heart Fail Rev
September 2025
Division of Provincial Cardiology, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Chemotherapy-induced cardiomyopathy (CHIC) represents a growing clinical challenge due to the increasing use of cardiotoxic treatments. These therapies can lead to progressive myocardial dysfunction, ultimately resulting in heart failure. Cardiac resynchronization therapy (CRT) has been widely investigated in selected patients with chronic heart failure; however, those with CHIC remain underrepresented in CRT trials.
View Article and Find Full Text PDFDevice Therapy in Patients with Heart Failure: Is Medication Use Optimized and Are We Targeting Those Patients Most Likely to Benefit?
CJC Open
August 2025
Division of General Internal Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Background: To determine what proportion of device-eligible patients with heart failure treated in a specialized clinic are on optimal guideline-directed medical therapy (GDMT) at the time of device referral and their benefit-risk status.
Methods: A cohort study was conducted of all patients seen between January 2013 and August 2024. We characterized GDMT by the modified Heart Function Collaboratory score at the time of device referral and grouped patients by Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-ICD) benefit-risk score.
Top Stories: Pediatric and Congenital Electrophysiology The Pursuit of Optimal Pacing Strategies in Congenitally Corrected Transposition.
Heart Rhythm
August 2025
Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.